Huawei is committed to integrating capital, technology, and industrial resources in the pharmaceutical industry, and collaborating with partners from all walks of life to create, invest, and achieve win-win outcomes.
Capital Empowerment & Commercialization
Joint capital investment to empower the commercialization of advanced drugs, meeting the growing clinical needs in China.
Integrating Resources, Promoting "Going Global" & "Bringing In"
Connecting domestic and international technology and capital, helping innovative domestic drugs "go global" and foreign advanced drugs "come in".
Huawei is a former subsidiary of the National Health Commission. Through years of development, it has established communication channels with relevant health authorities.
Established good communication and cooperation with the Chinese Center for Disease Control and Prevention, providing professional insights and resource support in disease prevention and public health.
Closely cooperates with the Chinese Pharmaceutical Association, Chinese Medical Doctor Association, etc., leveraging these ties to gather abundant expert resources.
CITIC Group and China Development Bank Capital have rich industrial investment experience, providing professional capital operation advice, strong financial support, and resource integration opportunities for projects.
Joining hands with industry giants such as China Resources, Shanghai Pharma, and Sinopharm to establish an efficient collaboration system, ensuring production handover for introduced products, building a commercial network, and accelerating product commercialization.
Through cooperation with CCFDIE, RDPAC, the China Pharmaceutical Enterprise Management Association, and the Chinese Pharmaceutical Association, connecting domestic and international enterprises.
Composed of senior industry professionals, we leverage deep expertise and extensive networks to provide diverse perspectives and guide project cooperation from strategy to execution.
Composed of experts from the National Medical Products Administration (NMPA) Drug and Medical Device Evaluation Center with extensive experience, providing professional policy interpretation and review guidance for company projects.
Experts from the Chinese Center for Disease Control and Prevention provide professional insights and support in relevant fields, helping to obtain more information and collaboration opportunities.
Professional investors from CITIC Group and China Development Bank Capital provide professional investment and financing advice for company projects.
Composed of experienced medical administration experts and foreign affairs experts, building cooperation bridges with top domestic and international medical institutions.
Relevant professionals from CCFDIE and the China Pharmaceutical Enterprise Management Association assist in connecting domestic and international pharmaceutical companies, providing professional guidance and advice.
Capital Empowerment & Commercialization
- Capital Empowerment: Joint capital investment
- Commercialization: Through in-license, CSO and other models, achieving complementary advantages and resources with innovative pharma companies, efficiently facilitating the commercial launch of new drugs.
Drug Collaboration with Multinational Companies
- Products discontinued due to domestic pharmaceutical policy and company strategy adjustments
- Drugs whose domestic general agency agreements have expired
- Patent-expired drugs
Introducing/Incubating Innovative Medical Device Products
- Introducing innovative medical devices with clinical needs and technical barriers
- Focusing on high-growth areas with technical barriers and clinical transformation potential, including diagnostics, therapeutics, neuromodulation, and brain-computer interfaces
- Accelerating product commercialization through registration pathway planning, clinical resource collaboration, and channel empowerment
Pharmaceutical Industry Investment
- Investment: Partnering with various stakeholders to jointly invest in quality pharmaceutical enterprises
- Empowerment: Empowering enterprises from multiple dimensions including capital, government affairs, industrial park policy support, and commercialization
Helping domestic innovative drugs seek cooperation opportunities with overseas pharmaceutical companies and capital, expanding into overseas markets.
Matching the needs of domestic pharma companies and Biotech, helping introduce advanced foreign drugs into China.
Address: 28th Floor, Nanyin Building, No. 2 East Third Ring North Road, Chaoyang District, Beijing
Phone: 010-61006202
Personnel recruitment consultation: li-ll@moh-hw.com
Investment and BD cooperation: BD@moh-hw.com
Medical sales consultation: zhang-b@moh-hw.com
Huawei Health Management Group. All Rights Reserved (C) 2021
Powered by PharmNet.com.cn Toocle NetSun Copyright Notice 京ICP备2026038759
Online Drug and Medical Device Information Service Filing: Non-commercial -(京) Online Drug and Device Information Record No. (2026) 00146